Todd E Golde

Todd E Golde

Professor, Director McKnight Brain Institute

Department: MD-NEUROSCIENCE-GENERAL
Business Phone: (352) 273-9456
Business Email: tgolde@ufl.edu

About Todd E Golde

Todd E. Golde, M.D., Ph.D., is director of the Evelyn F. and William L. McKnight Brain Institute (MBI) of the University of Florida, where he oversees, champions and facilitates neuroscience and neuromedicine research programs across the UF campus. A professor of neuroscience and neurology, Dr. Golde joined the UF faculty in 2009 and became founding director of UF’s Center for Translational Research in Neurodegenerative Disease (CTRND), which he led until taking the helm at the MBI in December 2016.

An internationally known expert in the scientific understanding of Alzheimer’s disease (AD), Dr. Golde has published more than 290 papers that have been cited more than 36,000 times. Over time his research has taken on a more transnational focus. He currently directs i) the NIH funded 1Florida Alzheimer’s Disease Research Center (ADRC, https://1floridaadrc.org/) that focuses on early detection and markers of progression in in diverse populations (especially Hispanics an African Americans) ii) a consortium U01 under the NIH’s accelerating medicine partnership AD program (AMP-AD) designed to identify novel targets in the immune systems in AD iii) studies exploring a novel immunotherapy targeting the HPA axis in AD , iv) the use of a novel brain slice culture model of tauopathy and α-synucleinopathy to identify therapeutic targets for the proteinopathies and the dysfunction that they cause, and v) an gene therapy approach to treating trigmenal neuralgia. Underlying his laboratory’s wet-bench research studies is the development of an extensive rAAV vector “toolkit” that enables us to accelerate translational preclinical studies that can help advance therapeutic discovery in many disease settings.

In addition to his research and intramural administrative activities, in recent years Dr. Golde has been an active advocate for AD and neurodegenerative disease research at the state, national and international levels. At the national level, he has served on the medical and scientific advisory board for the National Alzheimer’s Association and he continue to do so for the Bright Focus Foundation. At the state level, he has served on several advisory boards relating to AD, and has worked to secure state support for Alzheimer’s research at UF as well as implement a statewide grants program to support AD research. Through his scientific reviews and presentations at national and international conferences, he not only discuss scientific advances, but also highlight the many challenges that we face in combating the AD epidemic (see, for example, Golde et al Alz Res & Therapy 2011, Golde et al Neuron 2011, Golde J. Neurochemistry 2016, Golde et al. Science 2018, Dawson et al Nature Neuroscience 2018, Golde, Neuron 2019).

Accomplishments

Director of the Evelyn F. and William L. McKnight Brain Institute
2017-current · University of Florida
Alzheimer's Research UK Drug Discovery Institutes Advisory board
2016-current · ARUK
Co-Organizer EMBO Conferences on Neurodegenerative disease
2015-2017 · EMBO
Faculty Research Award Basic Science
2014 · UF College of Medicine
Medical and Scientific Advisory Council for the National Alzheimer’s Association
2012-2019 · National Alzheimer's Assocaition
Purple Ribbon Task Force for Alzheimer’s Disease
2012-2013 · Florida Speaker of the House of Representatives Appointment
Alzheimer’s Disease Advisory Committee (ADI)
2010-2016 · State of Florida, Department of Elder Affairs, Governor's Appointment
Founding Director, Center for Translational Research in Neurodegenerative disease
2010-2016 · University of Florida
Met Life Award for Medical Research
2010 · Met Life Foundation
Stephen DeArmond Lecturer
2010 · American Association of Neuropathology
Thome Award in Alzheimer's Disease Drug Discovery Research
2010 · Edward N. and Della L. Thome Memorial Foundation
Founding Co-Editor in Chief – Alzheimer’s Research and Therapy
2009-2019 · BMC
Consulting Editor – Journal of Clinical Investigator
2007-Current · American Society for Clinical Investigation
Coins for Alzheimer's Research Trust
2007 · Rotary Clubs of America
BrightFocus Foundation Alzheimer’s Advisory Board
2006-Current · BrightFocus Foundation
Chair , Department of Neuroscience
2003-2009 · Mayo Clinic Florida
Outstanding Contributor, Alzheimer’s Research Forum
2001 · Alzheimer's Research Forum
Graduate Education Coordinator, Mayo Clinic Florida
1999-2003 · Mayo Clinic
Ellison Medical Foundation New Scholar
1998 · Ellison Medical Foundation
Paul Beeson Physician Faculty Scholar
1997 · American Federation for Aging Research
Zenith Award
1995 · Alzheimer’s Association
Experimental Pathologist-in-Training Award
1993 · American Society for Investigative Pathology
The Oscar E. Schotte Award, Awarded to a senior student for the outstanding Honor's thesis in the Department of Biology.
1985 · Amherst College

Research Profile

CONTRIBUTIONS TO SCIENCE 1. As a MD PhD student and postdoc with Dr. Steven Younkin, I played a pivotal role in studies showing that the amyloid beta protein (Abeta) was a normal metabolite and that mutations that cause AD alter Abeta production in a manner that promote Abeta aggregation. These studies provided pivotal support for the Abeta aggregate (amyloid) hypothesis of AD and enabled drug discovery programs aimed at altering Abeta accumulation. a) Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 1992;255(5045):728-30. doi: 10.1126/science.1738847. PubMed PMID: 1738847. b) Shoji M*, Golde TE*, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992;258(5079):126-9. doi: 10.1126/science.1439760. PubMed PMID: 1439760.. c) Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 1993;259(5094):514-6. doi: 10.1126/science.8424174. PubMed PMID: 8424174. d) Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264(5163):1336-40. doi: 10.1126/science.8191290. PubMed PMID: 8191290. 2. In studies conducted in collaboration with Dr. Edward Koo’s laboratory (UCSD), we demonstrated that select non-steroidal anti-inflammatory agents (NSAIDs) could modulate Abeta42 production and that this effect was attributable to direct alteration of gamma-secretase activity. Subsequently we identified compounds that lowered Abeta42 but lacked cyclooxygenase activity, we also described compounds with the opposite effect that raise Aβ42 levels, and finally that these compounds work in part by targeting substrate. These data and modeling studies on the biological properties of “short” Aβ peptides has supported the rationale for development and testing of what are now referred to as gamma-secretase modulators (GSMs) as potential therapeutics for AD. a) Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414(6860):212-6. doi: 10.1038/35102591. PubMed PMID: 11700559. b) Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005;11(5):545-50. Epub 2005/04/17. doi: 10.1038/nm1235. PubMed PMID: 15834426. c) Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, Verbeeck C, Yager D, Eckman C, Ye W, Sagi S, Cottrell BA, Torpey J, Rosenberry TL, Fauq A, Wolfe MS, Schmidt B, Walsh DM, Koo EH, Golde TE. Substrate-targeting gamma-secretase modulators. Nature. 2008;453(7197):925-9. doi: 10.1038/nature07055. PubMed PMID: 18548070; PMCID: PMC2678541. d) Moore BD, Martin J, de Mena L, Sanchez J, Cruz PE, Ceballos-Diaz C, Ladd TB, Ran Y, Levites Y, Kukar TL, Kurian JJ, McKenna R, Koo EH, Borchelt DR, Janus C, Rincon-Limas D, Fernandez-Funez P, Golde TE. Short Aβ peptides attenuate Aβ42 toxicity in vivo. J Exp Med. 2018;215(1):283-301. Epub 2017/12/05. doi: 10.1084/jem.20170600. PubMed PMID: 29208777; PMCID: PMC5748850.3. 3. A parallel area of interest to GSMs has been the therapeutic utility of targeting intramembrane cleaving proteases in a variety of indications. In 2002, in collaboration with Dr. Chris Ponting, we identified a family of intramembrane protease (presenilin homologs/signal peptide peptidases) that was related to gamma-secretase. In work conducted in collaboration with Drs. Osborne (UMASS), Miele (LSU/Tulane), and Greenbaum (U Penn), we have evaluated targeting these proteases in cancer, immunologic disease, and malaria. a) Ponting CP, Hutton M, Nyborg A, Baker M, Jansen K, Golde TE. Identification of a novel family of presenilin homologues. Hum Mol Genet. 2002;11(9):1037-44. doi: 10.1093/hmg/11.9.1037. PubMed PMID: 11978763. b) Das P, Verbeeck C, Minter L, Chakrabarty P, Felsenstein K, Kukar T, Maharvi G, Fauq A, Osborne BA, Golde TE. Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener. 2012;7:39. Epub 2012/08/14. doi: 10.1186/1750-1326-7-39. PubMed PMID: 22892055; PMCID: PMC3477045. c) R Harbut MB, Patel BA, Yeung BK, McNamara CW, Bright AT, Ballard J, Supek F, Golde TE, Winzeler EA, Diagana TT, Greenbaum DC. Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design. Proc Natl Acad Sci U S A. 2012;109(52):21486-91. Epub 2012/12/11. doi: 10.1073/pnas.1216016110. PubMed PMID: 23236186; PMCID: PMC3535666. d) Ran Y, Hossain F, Pannuti A, Lessard CB, Ladd GZ, Jung JI, Minter LM, Osborne BA, Miele L, Golde TE. γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol Med. 2017;9(7):950-66. doi: 10.15252/emmm.201607265. PubMed PMID: 28539479; PMCID: PMC5494507. 4. My laboratory has been at the forefront of developing rAAV-based models and delivery of biotherapeutics to the brain, spinal cord and muscle. Much of this work has focused on delivery of potentially biotherapeutic molecules to models of Alzheimer’s disease. We continue to revise and update this technology, and our most recent study describes using minimally purified rAAV for both in vitro and ex vivo studies, which will enable rAAV technology to be much more accessible to the wider community. a) Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci. 2006;26(46):11923-8. doi: 10.1523/JNEUROSCI.2795-06.2006. PubMed PMID: 17108166; PMCID: PMC6674861. b) Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, Jansen K, Borchelt DR, Kim JY, Jankowsky JL, Golde TE, Levites Y. Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS One. 2013;8(6):e67680. Epub 2013/06/25. doi: 10.1371/journal.pone.0067680. PubMed PMID: 23825679; PMCID: PMC3692458. c) Ayers JI, Fromholt S, Sinyavskaya O, Siemienski Z, Rosario AM, Li A, Crosby KW, Cruz PE, DiNunno NM, Janus C, Ceballos-Diaz C, Borchelt DR, Golde TE, Chakrabarty P, Levites Y. Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice. Mol Ther. 2015;23(1):53-62. Epub 2014/09/17. doi: 10.1038/mt.2014.180. PubMed PMID: 25228069; PMCID: PMC4426802. d) Goodwin MS, Croft CL, Futch HS, Ryu D, Ceballos-Diaz C, Liu X, Paterno G, Mejia C, Deng D, Menezes K, Londono L, Arjona K, Parianos M, Truong V, Rostonics E, Hernandez A, Boye SL, Boye SE, Levites Y, Cruz PE, Golde TE. Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS. Mol Neurodegener. 2020;15(1):15. Epub 2020/03/02. doi: 10.1186/s13024-020-00361-z. PubMed PMID: 32122372; PMCID: PMC7053119. 5. Over the last 10 years, my research has expanded into the area of innate immunity’s role in neurodegenerative disease. Recent work from my lab has challenged a long-standing hypothesis that inflammatory processes in AD accelerate Aβ deposition. Published studies also reveal a potential novel role of interferon-gamma in nigrostriatal degeneration and novel roles for decoy receptors in AD. We have now expanded these studies to broadly explore immune modulators as mediators of neurodegenerative pathways. a) Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010;24(2):548-59. Epub 2009/10/13. doi: 10.1096/fj.09-141754. PubMed PMID: 19825975; PMCID: PMC3083918. b) Chakrabarty P, Ceballos-Diaz C, Lin WL, Beccard A, Jansen-West K, McFarland NR, Janus C, Dickson D, Das P, Golde TE. Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification. Nat Neurosci. 2011;14(6):694-6. Epub 2011/05/15. doi: 10.1038/nn.2829. PubMed PMID: 21572432; PMCID: PMC3780582. c) Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD, Funk CC, Cruz PE, Allen M, Yaroshenko M, Wang X, Younkin C, Reddy J, Lohrer B, Mehrke L, Moore BD, Liu X, Ceballos-Diaz C, Rosario AM, Medway C, Janus C, Li HD, Dickson DW, Giasson BI, Price ND, Younkin SG, Ertekin-Taner N, Golde TE. TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease. J Exp Med. 2018;215(9):2247-64. doi: 10.1084/jem.20180484. PubMed PMID: 30158114; PMCID: PMC6122970. d) Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND, Das P, Golde TE. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85(3):519-33. Epub 2015/01/22. doi: 10.1016/j.neuron.2014.11.020. PubMed PMID: 25619653; PMCID: PMC4320003.

Open Researcher and Contributor ID (ORCID)

0000-0003-1867-7071

Areas of Interest
  • Adeno-Associated Viral Gene Therapy
  • Alzheimer’s Disease
  • Cancer Therapeutics
  • Dementia
  • Immunoproteostasis
  • Neurodegenerative diseases
  • Neuroimmune interactions in Neurodegenerative diseases
  • Trigeminal Neuralgia
  • intramembrane cleaving proteases

Publications

2020
Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.
Molecular therapy : the journal of the American Society of Gene Therapy. [DOI] 10.1016/j.ymthe.2020.10.007. [PMID] 33128896.
2020
γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not.
Alzheimer's research & therapy. 12(1) [DOI] 10.1186/s13195-020-00622-5. [PMID] 32430033.
2020
Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS.
Molecular neurodegeneration. 15(1) [DOI] 10.1186/s13024-020-00361-z. [PMID] 32122372.
2020
Utility of Plasma Neurofilament Light in the 1Florida Alzheimer’s Disease Research Center (ADRC).
Journal of Alzheimer's disease : JAD. [DOI] 10.3233/JAD-200901. [PMID] 33216030.
2020
Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer’s Association and the scientific community.
Alzheimer's & dementia : the journal of the Alzheimer's Association. 16(7):1095-1098 [DOI] 10.1002/alz.12059. [PMID] 32426924.
2020
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis.
JAMA neurology. [DOI] 10.1001/jamaneurol.2020.3536. [PMID] 33074286.
2020
Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice.
Proceedings of the National Academy of Sciences of the United States of America. 117(31):18591-18599 [DOI] 10.1073/pnas.2005748117. [PMID] 32690681.
2020
Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models.
Cell reports. 32(2) [DOI] 10.1016/j.celrep.2020.107908. [PMID] 32668255.
2020
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation.
Nature medicine. 26(5):769-780 [DOI] 10.1038/s41591-020-0815-6. [PMID] 32284590.
2020
Atlas of Transcription Factor Binding Sites from ENCODE DNase Hypersensitivity Data across 27 Tissue Types.
Cell reports. 32(7) [DOI] 10.1016/j.celrep.2020.108029. [PMID] 32814038.
2020
Fyn depletion ameliorates tauP301L-induced neuropathology.
Acta neuropathologica communications. 8(1) [DOI] 10.1186/s40478-020-00979-6. [PMID] 32665013.
2020
Do infections have a role in the pathogenesis of Alzheimer disease?
Nature reviews. Neurology. 16(4):193-197 [DOI] 10.1038/s41582-020-0323-9. [PMID] 32152461.
2020
Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis.
Acta neuropathologica communications. 8(1) [DOI] 10.1186/s40478-020-00911-y. [PMID] 32252825.
2020
Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-γ.
Brain structure & function. 225(1):427-439 [DOI] 10.1007/s00429-019-02017-1. [PMID] 31894407.
2020
CD28 Signaling Drives Notch Ligand Expression on CD4 T Cells.
Frontiers in immunology. 11 [DOI] 10.3389/fimmu.2020.00735. [PMID] 32457739.
2020
Aß40 displays amyloidogenic properties in the non-transgenic mouse brain but does not exacerbate Aß42 toxicity in Drosophila.
Alzheimer's research & therapy. 12(1) [DOI] 10.1186/s13195-020-00698-z. [PMID] 33069251.
2020
Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy.
Molecular neurobiology. 57(4):1986-2001 [DOI] 10.1007/s12035-019-01859-4. [PMID] 31903524.
2019
rAAV-based brain slice culture models of Alzheimer’s and Parkinson’s disease inclusion pathologies.
The Journal of experimental medicine. 216(3):539-555 [DOI] 10.1084/jem.20182184. [PMID] 30770411.
2019
Phosphorylation of serine 305 in tau inhibits aggregation.
Neuroscience letters. 692:187-192 [DOI] 10.1016/j.neulet.2018.11.011. [PMID] 30423399.
2019
Organotypic brain slice cultures to model neurodegenerative proteinopathies.
Molecular neurodegeneration. 14(1) [DOI] 10.1186/s13024-019-0346-0. [PMID] 31791377.
2019
Neurite orientation dispersion and density imaging reveals white matter and hippocampal microstructure changes produced by Interleukin-6 in the TgCRND8 mouse model of amyloidosis.
NeuroImage. 202 [DOI] 10.1016/j.neuroimage.2019.116138. [PMID] 31472250.
2019
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Laboratory investigation; a journal of technical methods and pathology. 99(7):912-928 [DOI] 10.1038/s41374-019-0197-x. [PMID] 30742061.
2019
Intra- and extracellular β-amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus.
Scientific reports. 9(1) [DOI] 10.1038/s41598-019-52324-0. [PMID] 31685865.
2019
Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau.
Molecular psychiatry. 24(9):1383-1397 [DOI] 10.1038/s41380-018-0258-3. [PMID] 30283031.
2019
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders.
Neuron. 101(6):1003-1015 [DOI] 10.1016/j.neuron.2019.02.027. [PMID] 30897353.
2019
Free-water imaging of the hippocampus is a sensitive marker of Alzheimer’s disease.
NeuroImage. Clinical. 24 [DOI] 10.1016/j.nicl.2019.101985. [PMID] 31470214.
2019
Individual and combined presenilin 1 and 2 knockouts reveal that both have highly overlapping functions in HEK293T cells.
The Journal of biological chemistry. 294(29):11276-11285 [DOI] 10.1074/jbc.RA119.008041. [PMID] 31167792.
2019
Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.
Human molecular genetics. 28(19):3255-3269 [DOI] 10.1093/hmg/ddz151. [PMID] 31261380.
2019
Cardiac MLC2 kinase is localized to the Z-disc and interacts with α-actinin2.
Scientific reports. 9(1) [DOI] 10.1038/s41598-019-48884-w. [PMID] 31467300.
2019
APP-Mediated Signaling Prevents Memory Decline in Alzheimer’s Disease Mouse Model.
Cell reports. 27(5):1345-1355.e6 [DOI] 10.1016/j.celrep.2019.03.087. [PMID] 31042463.
2019
An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes.
The Journal of experimental medicine. 216(11):2479-2491 [DOI] 10.1084/jem.20190430. [PMID] 31467037.
2019
Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.
Alzheimer's research & therapy. 11(1) [DOI] 10.1186/s13195-019-0469-0. [PMID] 30711010.
2019
ALS-Linked SOD1 Mutants Enhance Neurite Outgrowth and Branching in Adult Motor Neurons.
iScience. 11:294-304 [DOI] 10.1016/j.isci.2018.12.026. [PMID] 30639851.
2019
ALS-Linked SOD1 Mutants Enhance Neurite Outgrowth and Branching in Adult Motor Neurons.
iScience. 19:448-449 [DOI] 10.1016/j.isci.2019.08.004. [PMID] 31425915.
2019
A cognitive stress test for prodromal Alzheimer’s disease: Multiethnic generalizability.
Alzheimer's & dementia (Amsterdam, Netherlands). 11:550-559 [DOI] 10.1016/j.dadm.2019.05.003. [PMID] 31417955.
2019
Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity.
NeuroImage. Clinical. 22 [DOI] 10.1016/j.nicl.2019.101800. [PMID] 30991618.
2018
Increased brain hemopexin levels improve outcomes after intracerebral hemorrhage.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 38(6):1032-1046 [DOI] 10.1177/0271678X16679170. [PMID] 27864463.
2018
Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration.
Neurobiology of disease. 120:98-106 [DOI] 10.1016/j.nbd.2018.09.005. [PMID] 30195075.
2018
Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
Frontiers in immunology. 9 [DOI] 10.3389/fimmu.2018.01288. [PMID] 29915603.
2018
Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways.
Frontiers in oncology. 8 [DOI] 10.3389/fonc.2018.00575. [PMID] 30564555.
2018
Notch1 primes CD4 T cells for T helper type I differentiation through its early effects on miR-29.
Molecular immunology. 99:191-198 [DOI] 10.1016/j.molimm.2018.05.002. [PMID] 29807327.
2018
Utilizing semantic intrusions to identify amyloid positivity in mild cognitive impairment.
Neurology. 91(10):e976-e984 [DOI] 10.1212/WNL.0000000000006128. [PMID] 30076274.
2018
Short Aβ peptides attenuate Aβ42 toxicity in vivo.
The Journal of experimental medicine. 215(1):283-301 [DOI] 10.1084/jem.20170600. [PMID] 29208777.
2018
TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease.
The Journal of experimental medicine. 215(9):2247-2264 [DOI] 10.1084/jem.20180484. [PMID] 30158114.
2018
Novel monoclonal antibodies targeting the microtubule-binding domain of human tau.
PloS one. 13(4) [DOI] 10.1371/journal.pone.0195211. [PMID] 29608591.
2018
Ifngr1 and Stat1 mediated canonical Ifn-γ signaling drives nigrostriatal degeneration.
Neurobiology of disease. 110:133-141 [DOI] 10.1016/j.nbd.2017.11.007. [PMID] 29196213.
2018
Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
The Journal of biological chemistry. 293(7):2408-2421 [DOI] 10.1074/jbc.M117.815357. [PMID] 29259137.
2018
Genome-wide pleiotropy analysis of neuropathological traits related to Alzheimer’s disease.
Alzheimer's research & therapy. 10(1) [DOI] 10.1186/s13195-018-0349-z. [PMID] 29458411.
2018
High-affinity interactions and signal transduction between Aβ oligomers and TREM2.
EMBO molecular medicine. 10(11) [DOI] 10.15252/emmm.201809027. [PMID] 30341064.
2018
Challenges in Passive Immunization Strategies to Treat Parkinson Disease.
JAMA neurology. 75(10):1180-1181 [DOI] 10.1001/jamaneurol.2018.0346. [PMID] 29913004.
2018
Conserved brain myelination networks are altered in Alzheimer’s and other neurodegenerative diseases.
Alzheimer's & dementia : the journal of the Alzheimer's Association. 14(3):352-366 [DOI] 10.1016/j.jalz.2017.09.012. [PMID] 29107053.
2018
Correction to: Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience.
Genome medicine. 10(1) [DOI] 10.1186/s13073-018-0516-7. [PMID] 29329552.
2018
Animal models of neurodegenerative diseases.
Nature neuroscience. 21(10):1370-1379 [DOI] 10.1038/s41593-018-0236-8. [PMID] 30250265.
2018
Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
The Journal of biological chemistry. 293(12) [DOI] 10.1074/jbc.AAC118.002657. [PMID] 29572329.
2018
Alzheimer’s disease: The right drug, the right time.
Science (New York, N.Y.). 362(6420):1250-1251 [DOI] 10.1126/science.aau0437. [PMID] 30545877.
2018
Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy.
Acta neuropathologica. 136(5):709-727 [DOI] 10.1007/s00401-018-1900-5. [PMID] 30136084.
2018
Designing antibodies against LRRK2-targeted tau epitopes.
PloS one. 13(9) [DOI] 10.1371/journal.pone.0204367. [PMID] 30261006.
2017
Parkinson Disease and Autoimmune Disorders-What Can We Learn From Genome-wide Pleiotropy?
JAMA neurology. 74(7):769-770 [DOI] 10.1001/jamaneurol.2017.0843. [PMID] 28586798.
2017
γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct.
EMBO molecular medicine. 9(7):950-966 [DOI] 10.15252/emmm.201607265. [PMID] 28539479.
2017
Targeting psychologic stress signaling pathways in Alzheimer’s disease.
Molecular neurodegeneration. 12(1) [DOI] 10.1186/s13024-017-0190-z. [PMID] 28633663.
2017
Recovery from Proactive Semantic Interference and MRI Volume: A Replication and Extension Study.
Journal of Alzheimer's disease : JAD. 59(1):131-139 [DOI] 10.3233/JAD-170276. [PMID] 28598850.
2017
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease.
Nature genetics. 49(9):1373-1384 [DOI] 10.1038/ng.3916. [PMID] 28714976.
2017
Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology.
Journal of neurochemistry. 140(4):662-678 [DOI] 10.1111/jnc.13743. [PMID] 27424880.
2017
Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer’s disease resilience.
Genome medicine. 9(1) [DOI] 10.1186/s13073-017-0486-1. [PMID] 29183403.
2017
Inflammatory pre-conditioning restricts the seeded induction of α-synuclein pathology in wild type mice.
Molecular neurodegeneration. 12(1) [DOI] 10.1186/s13024-016-0142-z. [PMID] 28049533.
2017
Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
Acta neuropathologica communications. 5(1) [DOI] 10.1186/s40478-017-0458-0. [PMID] 28760159.
2017
Amyloid β peptides overexpression in retinal pigment epithelial cells via AAV-mediated gene transfer mimics AMD-like pathology in mice.
Scientific reports. 7(1) [DOI] 10.1038/s41598-017-03397-2. [PMID] 28607377.
2017
A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies.
PloS one. 12(9) [DOI] 10.1371/journal.pone.0184731. [PMID] 28910367.
2017
A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking.
PloS one. 12(5) [DOI] 10.1371/journal.pone.0173565. [PMID] 28467418.
2017
A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer’s disease risk and increased TREML1 and TREM2 brain gene expression.
Alzheimer's & dementia : the journal of the Alzheimer's Association. 13(6):663-673 [DOI] 10.1016/j.jalz.2016.10.005. [PMID] 27939925.
2017
Intrastriatal injection of α-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity.
Molecular neurodegeneration. 12(1) [DOI] 10.1186/s13024-017-0182-z. [PMID] 28552073.
2016
Increased brain hemopexin levels improve outcomes after intracerebral hemorrhage
Journal of Cerebral Blood Flow and Metabolism.
2016
Overcoming translational barriers impeding development of Alzheimer’s disease modifying therapies.
Journal of neurochemistry. 139 Suppl 2:224-236 [DOI] 10.1111/jnc.13583. [PMID] 27145445.
2016
Microglia-specific targeting by novel capsid-modified AAV6 vectors.
Molecular therapy. Methods & clinical development. 3 [DOI] 10.1038/mtm.2016.26. [PMID] 27308302.
2016
Microglia-Specific Targeting By Novel Capsid- Modified Aav6 Vectors
. 3 [DOI] 10.1038/mtm.2016.26. [PMID] 27308302.
2016
Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases.
Scientific data. 3 [DOI] 10.1038/sdata.2016.89. [PMID] 27727239.
2016
Non-prion-type transmission in A53T α-synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust α-synuclein pathology.
Acta neuropathologica. 131(1):151-4 [DOI] 10.1007/s00401-015-1505-1. [PMID] 26541429.
2016
Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci.
Acta neuropathologica. 132(2):197-211 [DOI] 10.1007/s00401-016-1576-7. [PMID] 27115769.
2016
Deficiency in either COX-1 or COX-2 genes does not affect amyloid beta protein burden in amyloid precursor protein transgenic mice.
Biochemical and biophysical research communications. 478(1):286-292 [DOI] 10.1016/j.bbrc.2016.07.015. [PMID] 27425247.
2016
Holdase activity of secreted Hsp70 masks amyloid-β42 neurotoxicity in Drosophila.
Proceedings of the National Academy of Sciences of the United States of America. 113(35):E5212-21 [DOI] 10.1073/pnas.1608045113. [PMID] 27531960.
2016
Cerebrospinal Biomarkers in Alzheimer Disease-Potential Roles as Markers of Prognosis and Neuroplasticity.
JAMA neurology. 73(5):508-10 [DOI] 10.1001/jamaneurol.2016.0090. [PMID] 27019279.
2016
Alzheimer disease: Host immune defence, amyloid-β peptide and Alzheimer disease.
Nature reviews. Neurology. 12(8):433-4 [DOI] 10.1038/nrneurol.2016.105. [PMID] 27418376.
2015
γ-Secretase Modulators and APH1 Isoforms Modulate γ-Secretase Cleavage but Not Position of ε-Cleavage of the Amyloid Precursor Protein (APP).
PloS one. 10(12) [DOI] 10.1371/journal.pone.0144758. [PMID] 26678856.
2015
Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice.
Molecular therapy : the journal of the American Society of Gene Therapy. 23(1):53-62 [DOI] 10.1038/mt.2014.180. [PMID] 25228069.
2015
Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice.
Molecular neurodegeneration. 10 [DOI] 10.1186/s13024-015-0026-7. [PMID] 26152284.
2015
The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity.
The EMBO journal. 34(12):1674-86 [DOI] 10.15252/embj.201488795. [PMID] 25964433.
2015
The stress response neuropeptide CRF increases amyloid-β production by regulating γ-secretase activity
Embo Journal. [DOI] 10.15252/embj.201488795. [PMID] 25964433.
2015
Studies of lipopolysaccharide effects on the induction of α-synuclein pathology by exogenous fibrils in transgenic mice.
Molecular neurodegeneration. 10 [DOI] 10.1186/s13024-015-0029-4. [PMID] 26223783.
2015
Re-Opening the Critical Window for Estrogen Therapy.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 35(49):16077-93 [DOI] 10.1523/JNEUROSCI.1890-15.2015. [PMID] 26658861.
2015
p53 Modulates Notch Signaling in MCF-7 Breast Cancer Cells by Associating With the Notch Transcriptional Complex Via MAML1.
Journal of cellular physiology. 230(12):3115-27 [DOI] 10.1002/jcp.25052. [PMID] 26033683.
2015
Murine Aβ over-production produces diffuse and compact Alzheimer-type amyloid deposits.
Acta neuropathologica communications. 3 [DOI] 10.1186/s40478-015-0252-9. [PMID] 26566997.
2015
Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans.
Alzheimer's research & therapy. 7(1) [DOI] 10.1186/s13195-015-0137-y. [PMID] 26244059.
2015
Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator.
Molecular neurodegeneration. 10 [DOI] 10.1186/s13024-015-0021-z. [PMID] 26169917.
2015
Increased free water in the substantia nigra of Parkinson’s disease: a single-site and multi-site study.
Neurobiology of aging. 36(2):1097-104 [DOI] 10.1016/j.neurobiolaging.2014.10.029. [PMID] 25467638.
2015
A Human Monoclonal Igg That Binds a Beta Assemblies and Diverse Amyloids Exhibits Anti-Amyloid Activities in Vitro and in Vivo
The Journal of Neuroscience. 35(16):6265-6276 [DOI] 10.1523/JNEUROSCI.5109-14.2015. [PMID] 25904780.
2015
A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 35(16):6265-76 [DOI] 10.1523/JNEUROSCI.5109-14.2015. [PMID] 25904780.
2015
Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer’s disease.
Human molecular genetics. 24(21):6093-105 [DOI] 10.1093/hmg/ddv321. [PMID] 26253732.
2015
Differential Inhibition of Signal Peptide Peptidase Family Members by Established γ-Secretase Inhibitors.
PloS one. 10(6) [DOI] 10.1371/journal.pone.0128619. [PMID] 26046535.
2015
Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission.
Acta neuropathologica. 130(2):303-5 [DOI] 10.1007/s00401-015-1444-x. [PMID] 25982997.
2015
IFN-γ promotes τ phosphorylation without affecting mature tangles.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 29(10):4384-98 [DOI] 10.1096/fj.15-275834. [PMID] 26156074.
2015
IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.
Neuron. 85(3):519-33 [DOI] 10.1016/j.neuron.2014.11.020. [PMID] 25619653.
2015
IFN-γ promotes τ phosphorylation without affecting mature tangles
The FASEB's Journal. [DOI] 10.1096/fj.15-275834. [PMID] 26156074.
2014
Independent relationship between amyloid precursor protein (APP) dimerization and γ-secretase processivity.
PloS one. 9(10) [DOI] 10.1371/journal.pone.0111553. [PMID] 25350374.
2014
γ-Secretase processing and effects of γ-secretase inhibitors and modulators on long Aβ peptides in cells.
The Journal of biological chemistry. 289(6):3276-87 [DOI] 10.1074/jbc.M113.512921. [PMID] 24352661.
2014
The effect of brief neonatal cryoanesthesia on physical development and adult cognitive function in mice.
Behavioural brain research. 259:253-60 [DOI] 10.1016/j.bbr.2013.11.010. [PMID] 24239696.
2014
NOTCH1 Can Initiate NF-κB Activation via Cytosolic Interactions with Components of the T Cell Signalosome.
Frontiers in immunology. 5 [DOI] 10.3389/fimmu.2014.00249. [PMID] 24904593.
2014
NOTCH1 Can Initiate NF-κB Activation via Cytosolic Interactions with Components of the T Cell Signalosome
Frontiers in Immunology. [DOI] 10.3389/fimmu.2014.00249. [PMID] 24904593.
2014
Non-Canonical Notch Signaling Drives Activation and Differentiation of Peripheral CD4(+) T Cells.
Frontiers in immunology. 5 [DOI] 10.3389/fimmu.2014.00054. [PMID] 24611064.
2014
Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice.
Proceedings of the National Academy of Sciences of the United States of America. 111(29):10732-7 [DOI] 10.1073/pnas.1321785111. [PMID] 25002524.
2014
Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction.
Journal of visualized experiments : JoVE. (91) [DOI] 10.3791/51863. [PMID] 25286085.
2014
Independent relationship between amyloid precursor protein (APP) dimerization and γ-secretase processivity
PLoS One. [DOI] 10.1371/journal.pone.0111553. [PMID] 25350374.
2014
Open questions for Alzheimer’s disease immunotherapy.
Alzheimer's research & therapy. 6(1) [DOI] 10.1186/alzrt233. [PMID] 24393284.
2014
Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
Journal of neurochemistry. 131(6):859-67 [DOI] 10.1111/jnc.12806. [PMID] 24984882.
2014
Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein
Journal of Neurochemistry. 131(136):859-867
2014
Differences in memory development among C57BL/6NCrl, 129S2/SvPasCrl, and FVB/NCrl mice after delay and trace fear conditioning.
Comparative medicine. 64(1):4-12 [PMID] 24672832.
View on: PubMed
2014
Differences in memory development among C57BL/6NCrl, 129S2/SvPasCrl, and FVB/NCrl mice after delay and trace fear conditioning
Comparative Medicine. 64(1):4-12
2014
Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulators.
Biochemistry. 53(12):1947-57 [DOI] 10.1021/bi401521t. [PMID] 24620716.
2014
Complex relationships between substrate sequence and sensitivity to alterations in γ-secretase processivity induced by γ-secretase modulators
Biochemistry (Washington, D.C. Online). [DOI] 10.1021/bi401521t. [PMID] 24620716.
2014
Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 34(37):12368-78 [DOI] 10.1523/JNEUROSCI.2102-14.2014. [PMID] 25209277.
2014
Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer’s disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 34(11):3826-40 [DOI] 10.1523/JNEUROSCI.5171-13.2014. [PMID] 24623762.
2014
Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.
Acta neuropathologica. 127(5):645-65 [PMID] 24659240.
View on: PubMed
2013
Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 33(9):3765-79 [DOI] 10.1523/JNEUROSCI.4251-12.2013. [PMID] 23447589.
2013
Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Acta neuropathologica. 126(1):39-50 [DOI] 10.1007/s00401-013-1123-8. [PMID] 23666556.
2013
The influence of 5-lipoxygenase on Alzheimer’s disease-related tau pathology: in vivo and in vitro evidence.
Biological psychiatry. 74(5):321-8 [DOI] 10.1016/j.biopsych.2012.12.012. [PMID] 23352590.
2013
Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia.
The Journal of experimental medicine. 210(7):1311-29 [DOI] 10.1084/jem.20112615. [PMID] 23733784.
2013
Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions.
Brain research. 1524:62-73 [DOI] 10.1016/j.brainres.2013.06.006. [PMID] 23774650.
2013
Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions
Brain Research.
2013
Progress in Alzheimer’s disease research circa 2013: Is the glass half empty or half full?
Alzheimers Research & Therapy. 5(3)
2013
Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo.
The European journal of neuroscience. 37(8):1203-20 [DOI] 10.1111/ejn.12126. [PMID] 23347239.
2013
γ-Secretase inhibitors and modulators.
Biochimica et biophysica acta. 1828(12):2898-907 [DOI] 10.1016/j.bbamem.2013.06.005. [PMID] 23791707.
2013
Thinking laterally about neurodegenerative proteinopathies.
The Journal of clinical investigation. 123(5):1847-55 [DOI] 10.1172/JCI66029. [PMID] 23635781.
2013
Progress in Alzheimer’s disease research circa 2013: Is the glass half empty or half full?
Alzheimer's research & therapy. 5(3) [DOI] 10.1186/alzrt180. [PMID] 23731836.
2013
Steroids as γ-secretase modulators.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 27(9):3775-85 [DOI] 10.1096/fj.12-225649. [PMID] 23716494.
2013
Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein.
Acta neuropathologica communications. 1 [DOI] 10.1186/2051-5960-1-38. [PMID] 24252149.
2013
Normal cognition in transgenic BRI2-Aβ mice.
Molecular neurodegeneration. 8 [DOI] 10.1186/1750-1326-8-15. [PMID] 23663320.
2013
Accelerated neurodegeneration through chaperone-mediated oligomerization of tau.
The Journal of clinical investigation. 123(10):4158-69 [DOI] 10.1172/JCI69003. [PMID] 23999428.
2013
Alzheimer’s disease risk alleles in TREM2 illuminate innate immunity in Alzheimer’s disease.
Alzheimer's research & therapy. 5(3) [DOI] 10.1186/alzrt178. [PMID] 23692967.
2013
Anti-tau antibodies: hitting the target.
Neuron. 80(2):254-6 [DOI] 10.1016/j.neuron.2013.10.009. [PMID] 24139027.
2013
Biomarkers for Alzheimer’s disease in plasma, serum and blood – conceptual and practical problems.
Alzheimer's research & therapy. 5(2) [DOI] 10.1186/alzrt164. [PMID] 23470193.
2013
Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”.
Science (New York, N.Y.). 340(6135):924-d [DOI] 10.1126/science.1234089. [PMID] 23704553.
2013
Conformational templating of α-synuclein aggregates in neuronal-glial cultures.
Molecular neurodegeneration. 8 [DOI] 10.1186/1750-1326-8-17. [PMID] 23714769.
2013
Fkbp51 Accelerates Alzheimer’s Disease Pathogenesis
Cell Transplantation. 22
2013
Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein
Acta Neuropathologica Communications. [DOI] 10.1186/2051-5960-1-38. [PMID] 24252149.
2013
Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain.
PloS one. 8(6) [DOI] 10.1371/journal.pone.0067680. [PMID] 23825679.
2012
Recent Alzheimer’s disease research highlights.
Alzheimer's research & therapy. 4(3) [DOI] 10.1186/alzrt117. [PMID] 22594696.
2012
Overlapping profiles of Aβ peptides in the Alzheimer’s disease and pathological aging brains.
Alzheimer's research & therapy. 4(3) [DOI] 10.1186/alzrt121. [PMID] 22621179.
2012
Notch signals in the endothelium and cancer “stem-like” cells: opportunities for cancer therapy.
Vascular cell. 4 [DOI] 10.1186/2045-824X-4-7. [PMID] 22487493.
2012
Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition.
Molecular neurodegeneration. 7 [DOI] 10.1186/1750-1326-7-36. [PMID] 22838967.
2012
Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Molecular neurodegeneration. 7 [DOI] 10.1186/1750-1326-7-53. [PMID] 23046583.
2012
Cyanobacterial peptides as a prototype for the design of potent β-secretase inhibitors and the development of selective chemical probes for other aspartic proteases.
Journal of medicinal chemistry. 55(23):10749-65 [DOI] 10.1021/jm301630s. [PMID] 23181502.
2012
Aβ alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo.
Nature communications. 3 [DOI] 10.1038/ncomms2013. [PMID] 22910355.
2012
Analysis of proteolytic processes and enzymatic activities in the generation of huntingtin n-terminal fragments in an HEK293 cell model.
PloS one. 7(12) [DOI] 10.1371/journal.pone.0050750. [PMID] 23236391.
2012
Alzheimer’s β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 32(33):11390-5 [PMID] 22895721.
View on: PubMed
2012
Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis.
Alzheimer's research & therapy. 4(3) [DOI] 10.1186/alzrt124. [PMID] 22697412.
2012
Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice
. 7(1)
2012
5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.
Annals of neurology. 72(3):442-54 [DOI] 10.1002/ana.23642. [PMID] 23034916.
2012
Retention in endoplasmic reticulum 1 (RER1) modulates amyloid-β (Aβ) production by altering trafficking of γ-secretase and amyloid precursor protein (APP).
The Journal of biological chemistry. 287(48):40629-40 [DOI] 10.1074/jbc.M112.418442. [PMID] 23043097.
2012
Analysis of Proteolytic Processes and Enzymatic Activities in the Generation of Huntingtin N-Terminal Fragments in An Hek293 Cell Model
PLoS One. 7 [DOI] 10.1371/journal.pone.0050750. [PMID] 23236391.
2012
Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice.
Molecular neurodegeneration. 7(1) [DOI] 10.1186/1750-1326-7-1. [PMID] 22222029.
2012
Shifting a complex debate on γ-secretase cleavage and Alzheimer’s disease.
The EMBO journal. 31(10):2237-9 [DOI] 10.1038/emboj.2012.111. [PMID] 22505028.
2012
Transient Pharmacologic Lowering of a Beta Production Prior To Deposition Results in Sustained Reduction of Amyloid Plaque Pathology
. 7 [DOI] 10.1186/1750-1326-7-39. [PMID] 22892055.
2012
Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology.
Molecular neurodegeneration. 7 [DOI] 10.1186/1750-1326-7-39. [PMID] 22892055.
2012
β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment.
EMBO molecular medicine. 4(9):980-91 [DOI] 10.1002/emmm.201101084. [PMID] 22903875.
2012
Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design.
Proceedings of the National Academy of Sciences of the United States of America. 109(52):21486-91 [DOI] 10.1073/pnas.1216016110. [PMID] 23236186.
2011
Substrate sequence influences γ-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein.
The Journal of biological chemistry. 286(46):39794-803 [DOI] 10.1074/jbc.M111.277228. [PMID] 21868380.
2011
Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-beta immunotherapy.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 31(11):4124-36 [DOI] 10.1523/JNEUROSCI.5077-10.2011. [PMID] 21411653.
2011
Right sizing funding for Alzheimer’s disease.
Alzheimer's research & therapy. 3(3) [DOI] 10.1186/alzrt76. [PMID] 21554753.
2011
Right sizing funding for Alzheimer’s disease
Alzheimers Research & Therapy. [DOI] 10.1186/alzrt76. [PMID] 21554753.
2011
Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification.
Nature neuroscience. 14(6):694-6 [DOI] 10.1038/nn.2829. [PMID] 21572432.
2011
Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid β peptide length: support for a sequential model of γ-secretase intramembrane proteolysis and regulation by the amyloid β precursor protein (APP) juxtamembrane region.
The Journal of biological chemistry. 286(46):39804-12 [DOI] 10.1074/jbc.M111.274696. [PMID] 21868378.
2011
Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo.
Molecular neurodegeneration. 6 [DOI] 10.1186/1750-1326-6-16. [PMID] 21324189.
2011
Anti-aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift.
Neuron. 69(2):203-13 [DOI] 10.1016/j.neuron.2011.01.002. [PMID] 21262461.
2011
Anesthetic propofol attenuates the isoflurane-induced caspase-3 activation and Aβ oligomerization.
PloS one. 6(11) [DOI] 10.1371/journal.pone.0027019. [PMID] 22069482.
2011
Anesthetic Propofol Attenuates the Isoflurane-Induced Caspase-3 Activation and a Beta Oligomerization
PLoS One. 6 [DOI] 10.1371/journal.pone.0027019. [PMID] 22069482.
2011
Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome.
PloS one. 6(12) [DOI] 10.1371/journal.pone.0027221. [PMID] 22174738.
2010
The secretases: enzymes with therapeutic potential in Alzheimer disease.
Nature reviews. Neurology. 6(2):99-107 [DOI] 10.1038/nrneurol.2009.218. [PMID] 20139999.
2010
Targeting Notch to target cancer stem cells.
Clinical cancer research : an official journal of the American Association for Cancer Research. 16(12):3141-52 [DOI] 10.1158/1078-0432.CCR-09-2823. [PMID] 20530696.
2010
Targeting Abeta and tau in Alzheimer’s disease, an early interim report.
Experimental neurology. 223(2):252-66 [DOI] 10.1016/j.expneurol.2009.07.035. [PMID] 19716367.
2010
Sorting out frontotemporal dementia?
Neuron. 68(4):601-3 [DOI] 10.1016/j.neuron.2010.11.014. [PMID] 21092851.
2010
Reduced Alzheimer’s disease ß-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(48):16160-9 [DOI] 10.1523/JNEUROSCI.4436-10.2010. [PMID] 21123562.
2010
Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.
Anticancer research. 30(10):3853-67 [PMID] 21036696.
View on: PubMed
2010
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 24(2):548-59 [DOI] 10.1096/fj.09-141754. [PMID] 19825975.
2010
IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice.
Journal of immunology (Baltimore, Md. : 1950). 184(9):5333-43 [DOI] 10.4049/jimmunol.0903382. [PMID] 20368278.
2010
Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain.
Journal of neuroscience methods. 194(1):144-53 [DOI] 10.1016/j.jneumeth.2010.10.010. [PMID] 20951738.
2010
Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(46):15374-82 [DOI] 10.1523/JNEUROSCI.3155-10.2010. [PMID] 21084594.
2009
Notch regulates cytolytic effector function in CD8+ T cells.
Journal of immunology (Baltimore, Md. : 1950). 182(6):3380-9 [DOI] 10.4049/jimmunol.0802598. [PMID] 19265115.
2009
Welcome to Alzheimer’s research & therapy.
Alzheimer's research & therapy. 1(1) [DOI] 10.1186/alzrt1. [PMID] 19671199.
2009
The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease.
Molecular neurodegeneration. 4 [DOI] 10.1186/1750-1326-4-8. [PMID] 19193222.
2009
Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer.
Advances in enzyme regulation. 49(1):134-41 [DOI] 10.1016/j.advenzreg.2009.01.008. [PMID] 19344631.
2009
Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia.
Nature neuroscience. 12(10):1300-7 [DOI] 10.1038/nn.2395. [PMID] 19734892.
2009
Signal peptide peptidases: a family of intramembrane-cleaving proteases that cleave type 2 transmembrane proteins.
Seminars in cell & developmental biology. 20(2):225-30 [DOI] 10.1016/j.semcdb.2009.02.003. [PMID] 19429495.
2009
Quantitative and mechanistic studies of Abeta immunotherapy.
CNS & neurological disorders drug targets. 8(1):31-49 [PMID] 19275635.
View on: PubMed
2009
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.
Blood. 113(8):1689-98 [DOI] 10.1182/blood-2008-03-147967. [PMID] 19001083.
2009
Medicine. Avoiding unintended toxicity.
Science (New York, N.Y.). 324(5927):603-4 [DOI] 10.1126/science.1174267. [PMID] 19407192.
2009
Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer’s and other neurodegenerative diseases.
Alzheimer's research & therapy. 1(2) [DOI] 10.1186/alzrt5. [PMID] 19822029.
2009
Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.
Cancer research. 69(6):2607-14 [DOI] 10.1158/0008-5472.CAN-08-2905. [PMID] 19276374.
2009
“What kills neurons in neurodegenerative diseases?”, a review series in an open access journal.
Molecular neurodegeneration. 4 [DOI] 10.1186/1750-1326-4-7. [PMID] 19193221.
2009
Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer’s disease.
Molecular therapy : the journal of the American Society of Gene Therapy. 17(12):2031-40 [DOI] 10.1038/mt.2009.174. [PMID] 19638957.
2009
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.
Molecular neurodegeneration. 4 [DOI] 10.1186/1750-1326-4-19. [PMID] 19419556.
2009
Avoiding unintended toxicity
Science.
2009
An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1.
Biochemistry. 48(46):10894-904 [DOI] 10.1021/bi901237k. [PMID] 19821615.
2009
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.
Proceedings of the National Academy of Sciences of the United States of America. 106(18):7607-12 [DOI] 10.1073/pnas.0900688106. [PMID] 19383787.
2009
A small molecule inhibitor of signal peptide peptidase inhibits Plasmodium development in the liver and decreases malaria severity.
PloS one. 4(4) [DOI] 10.1371/journal.pone.0005078. [PMID] 19337374.
2009
Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology.
Neurobiology of disease. 34(1):163-77 [PMID] 19320056.
View on: PubMed
2008
Transthyretin protects Alzheimer’s mice from the behavioral and biochemical effects of Abeta toxicity.
Proceedings of the National Academy of Sciences of the United States of America. 105(7):2681-6 [DOI] 10.1073/pnas.0712197105. [PMID] 18272491.
2008
Substrate-targeting gamma-secretase modulators.
Nature. 453(7197):925-9 [DOI] 10.1038/nature07055. [PMID] 18548070.
2008
Rational targeting of Notch signaling in cancer.
Oncogene. 27(38):5124-31 [DOI] 10.1038/onc.2008.226. [PMID] 18758481.
2008
Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage.
Current topics in medicinal chemistry. 8(1):47-53 [PMID] 18220932.
View on: PubMed
2008
Off the beaten pathway: the complex cross talk between Notch and NF-kappaB.
Laboratory investigation; a journal of technical methods and pathology. 88(1):11-7 [PMID] 18059366.
View on: PubMed
2008
Using leucine zipper to facilitate alpha-synuclein assembly.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 22(9):3165-74 [DOI] 10.1096/fj.08-108365. [PMID] 18492724.
2008
Notch signaling is activated by TLR stimulation and regulates macrophage functions.
European journal of immunology. 38(1):174-83 [PMID] 18085664.
View on: PubMed
2008
Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase.
The Journal of biological chemistry. 283(25):17049-54 [DOI] 10.1074/jbc.M802912200. [PMID] 18426795.
2008
ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Oncogene. 27(37):5019-32 [DOI] 10.1038/onc.2008.149. [PMID] 18469855.
2008
BRI2 (ITM2b) inhibits Abeta deposition in vivo.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 28(23):6030-6 [DOI] 10.1523/JNEUROSCI.0891-08.2008. [PMID] 18524908.
2008
A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains.
Proceedings of the National Academy of Sciences of the United States of America. 105(30):10595-600 [DOI] 10.1073/pnas.0803671105. [PMID] 18647832.
2008
Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells.
Blood. 112(5):1813-21 [DOI] 10.1182/blood-2008-03-144980. [PMID] 18550850.
2007
The pathogenesis of Alzheimer’s disease and the role of Abeta42.
CNS spectrums. 12(1 Suppl 1):4-6 [PMID] 17192766.
View on: PubMed
2007
Statins reduce amyloid-beta production through inhibition of protein isoprenylation.
The Journal of biological chemistry. 282(37):26832-44 [PMID] 17646164.
View on: PubMed
2007
Novel rat Alzheimer’s disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels.
Molecular neurodegeneration. 2 [PMID] 17559680.
View on: PubMed
2007
Notch inhibition in Kaposi’s sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-kappaB signaling.
Molecular cancer therapeutics. 6(7):1983-92 [PMID] 17604336.
View on: PubMed
2007
Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals.
Alzheimer disease and associated disorders. 21(4):292-9 [PMID] 18090435.
View on: PubMed
2007
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.
BMC neuroscience. 8 [PMID] 17650315.
View on: PubMed
2007
Abeta40 inhibits amyloid deposition in vivo.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 27(3):627-33 [PMID] 17234594.
View on: PubMed
2007
A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers.
Bioorganic & medicinal chemistry letters. 17(22):6392-5 [PMID] 17897827.
View on: PubMed
2007
Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase.
The Journal of biological chemistry. 282(44):32264-73 [PMID] 17827153.
View on: PubMed
2006
Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel gamma-secretase substrates.
Molecular neurodegeneration. 1 [PMID] 16930450.
View on: PubMed
2006
Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs.
Biochemistry. 45(28):8649-56 [PMID] 16834339.
View on: PubMed
2006
Signal peptide peptidase (SPP) dimer formation as assessed by fluorescence lifetime imaging microscopy (FLIM) in intact cells.
Molecular neurodegeneration. 1 [PMID] 17105660.
View on: PubMed
2006
Notch1 augments NF-kappaB activity by facilitating its nuclear retention.
The EMBO journal. 25(1):129-38 [PMID] 16319921.
View on: PubMed
2006
Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy.
Journal of neuroinflammation. 3 [PMID] 16872492.
View on: PubMed
2006
Matrix metalloproteinase-9 contributes to brain extravasation and edema in fulminant hepatic failure mice.
Journal of hepatology. 44(6):1105-14 [PMID] 16458990.
View on: PubMed
2006
Intramembrane proteolytic cleavage by human signal peptide peptidase like 3 and malaria signal peptide peptidase.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 20(10):1671-9 [PMID] 16873890.
View on: PubMed
2006
Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 26(46):11923-8 [PMID] 17108166.
View on: PubMed
2006
Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer’s disease mouse models.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 20(14):2576-8 [PMID] 17068112.
View on: PubMed
2006
Notch signaling in cancer.
Current molecular medicine. 6(8):905-18 [PMID] 17168741.
View on: PubMed
2006
Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether?
Neurology. 66(2 Suppl 1):S65-8 [PMID] 16432148.
View on: PubMed
2006
Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42.
Journal of neurochemistry. 96(2):355-65 [PMID] 16300630.
View on: PubMed
2006
C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation.
Journal of neurochemistry. 96(1):218-27 [PMID] 16305624.
View on: PubMed
2006
Detection of presenilin-1 homodimer formation in intact cells using fluorescent lifetime imaging microscopy.
Biochemical and biophysical research communications. 340(2):668-74 [PMID] 16376853.
View on: PubMed
2006
Disease modifying therapy for AD?
Journal of neurochemistry. 99(3):689-707 [PMID] 17076654.
View on: PubMed
2006
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
The Journal of clinical investigation. 116(1):193-201 [PMID] 16341263.
View on: PubMed
2006
Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins.
Molecular therapy : the journal of the American Society of Gene Therapy. 13(3):517-27 [PMID] 16325474.
View on: PubMed
2006
Filling the gaps in the abeta cascade hypothesis of Alzheimer’s disease.
Current Alzheimer research. 3(5):421-30 [PMID] 17168641.
View on: PubMed
2006
Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study.
Brain : a journal of neurology. 129(Pt 11):3103-14 [PMID] 17030535.
View on: PubMed
2006
Dysfunction of TGF-beta signaling in Alzheimer’s disease.
The Journal of clinical investigation. 116(11):2855-7 [PMID] 17080189.
View on: PubMed
2005
Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.
Neuron. 47(2):191-199 [DOI] 10.1016/j.neuron.2005.06.030. [PMID] 16039562.
2005
Bringing amyloid into focus.
Nature biotechnology. 23(5):552-4 [PMID] 15877070.
View on: PubMed
2005
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.
Nature medicine. 11(5):545-50 [PMID] 15834426.
View on: PubMed
2005
Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi’s sarcoma tumor cells.
Oncogene. 24(42):6333-44 [PMID] 15940249.
View on: PubMed
2005
Homing in on intracellular Abeta?
Neuron. 45(5):639-42 [PMID] 15748837.
View on: PubMed
2005
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21.
Nature immunology. 6(7):680-8 [PMID] 15991363.
View on: PubMed
2005
The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease.
Brain pathology (Zurich, Switzerland). 15(1):84-7 [PMID] 15779241.
View on: PubMed
2004
Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity.
Biochemical and biophysical research communications. 322(4):1145-52 [PMID] 15336962.
View on: PubMed
2004
Signal peptide peptidase forms a homodimer that is labeled by an active site-directed gamma-secretase inhibitor.
The Journal of biological chemistry. 279(15):15153-60 [PMID] 14704149.
View on: PubMed
2004
A signal peptide peptidase (SPP) reporter activity assay based on the cleavage of type II membrane protein substrates provides further evidence for an inverted orientation of the SPP active site relative to presenilin.
The Journal of biological chemistry. 279(41):43148-56 [PMID] 15252014.
View on: PubMed
2003
Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.
The Journal of biological chemistry. 278(33):30748-54 [PMID] 12777371.
View on: PubMed
2003
Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.
Neuron. 39(3):409-21 [PMID] 12895417.
View on: PubMed
2003
The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production.
The Journal of biological chemistry. 278(34):31825-30 [PMID] 12805355.
View on: PubMed
2003
TCR-mediated Notch signaling regulates proliferation and IFN-gamma production in peripheral T cells.
Journal of immunology (Baltimore, Md. : 1950). 171(6):3019-24 [PMID] 12960327.
View on: PubMed
2003
Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis.
Science's STKE : signal transduction knowledge environment. 2003(172) [PMID] 12621149.
View on: PubMed
2003
Overexpression of nicastrin increases Abeta production.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 17(9):1138-40 [PMID] 12692078.
View on: PubMed
2003
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.
The Journal of clinical investigation. 112(3):440-9 [PMID] 12897211.
View on: PubMed
2003
Peptide-based, irreversible inhibitors of gamma-secretase activity.
Biochemical and biophysical research communications. 305(3):529-33 [PMID] 12763025.
View on: PubMed
2003
Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies.
Neurobiology of aging. 24(7):969-76 [PMID] 12928057.
View on: PubMed
2003
Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity.
The Journal of biological chemistry. 278(34):31831-7 [PMID] 12805356.
View on: PubMed
2003
Androgens modulate beta-amyloid levels in male rat brain.
Journal of neurochemistry. 87(4):1052-5 [PMID] 14622134.
View on: PubMed
2003
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(24):8532-8 [PMID] 13679422.
View on: PubMed
2003
Alzheimer disease therapy: can the amyloid cascade be halted?
The Journal of clinical investigation. 111(1):11-8 [PMID] 12511580.
View on: PubMed
2003
Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs.
Human molecular genetics. 12 Spec No 2:R201-6 [PMID] 12966028.
View on: PubMed
2002
Identification of a novel family of presenilin homologues.
Human molecular genetics. 11(9):1037-44 [PMID] 11978763.
View on: PubMed
2002
Inflammation takes on Alzheimer disease.
Nature medicine. 8(9):936-8 [PMID] 12205453.
View on: PubMed
2002
Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle.
Proceedings of the National Academy of Sciences of the United States of America. 99(9):6334-9 [PMID] 11972038.
View on: PubMed
2002
Familial frontotemporal dementia associated with a novel presenilin-1 mutation.
Dementia and geriatric cognitive disorders. 14(1):13-21 [PMID] 12053127.
View on: PubMed
2002
Open peer commentary regarding Abeta immunization and CNS inflammation by Pasinetti et al.
Neurobiology of aging. 23(5):671-4; discussion 683 [PMID] 12392769.
View on: PubMed
2002
Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains.
Neurobiology of disease. 9(1):11-23 [PMID] 11848681.
View on: PubMed
2002
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP.
Proceedings of the National Academy of Sciences of the United States of America. 99(7):4697-702 [PMID] 11917117.
View on: PubMed
2002
FAD-linked mutations in presenilin 1 alter the length of Abeta peptides derived from betaAPP transmembrane domain mutants.
Biochimica et biophysica acta. 1586(2):199-209 [PMID] 11959461.
View on: PubMed
2002
A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch.
Neurobiology of disease. 9(2):269-73 [PMID] 11895378.
View on: PubMed
2001
A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor.
The Journal of biological chemistry. 276(1):481-7 [PMID] 11035007.
View on: PubMed
2001
Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer’s disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 15(1):16-18 [PMID] 11099491.
View on: PubMed
2001
Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.
Neurobiology of aging. 22(5):721-7 [PMID] 11705631.
View on: PubMed
2001
Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion.
The Journal of biological chemistry. 276(42):38563-9 [PMID] 11504726.
View on: PubMed
2001
gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase.
Science (New York, N.Y.). 294(5549):2179-81 [PMID] 11679632.
View on: PubMed
2001
Presenilins as therapeutic targets for the treatment of Alzheimer’s disease.
Trends in molecular medicine. 7(6):264-9 [PMID] 11378516.
View on: PubMed
2001
Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase.
The Journal of neuroscience : the official journal of the Society for Neuroscience. 21(14):4987-95 [PMID] 11438574.
View on: PubMed
2001
Cholesterol modulation as an emerging strategy for the treatment of Alzheimer’s disease.
Drug discovery today. 6(20):1049-1055 [PMID] 11590033.
View on: PubMed
2001
beta-Secretase cleavage of the amyloid precursor protein mediates neuronal apoptosis caused by familial Alzheimer’s disease mutations.
Brain research. Molecular brain research. 97(1):103-13 [PMID] 11744168.
View on: PubMed
2001
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Nature. 414(6860):212-6 [PMID] 11700559.
View on: PubMed
2001
Expression of BRI-amyloid beta peptide fusion proteins: a novel method for specific high-level expression of amyloid beta peptides.
Biochimica et biophysica acta. 1537(1):58-62 [PMID] 11476963.
View on: PubMed
2001
High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer’s amyloid beta peptide (Abeta).
Journal of neuroscience methods. 108(2):171-9 [PMID] 11478976.
View on: PubMed
2000
Variant Alzheimer’s disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations.
Annals of neurology. 48(5):806-8 [PMID] 11079548.
View on: PubMed
2000
An empirical model of gamma-secretase activity.
Annals of the New York Academy of Sciences. 920:233-40 [PMID] 11193156.
View on: PubMed
2000
Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease.
Biochimica et biophysica acta. 1502(1):172-87 [PMID] 10899442.
View on: PubMed
2000
Cell-free assays for gamma-secretase activity.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 14(15):2383-6 [PMID] 11024004.
View on: PubMed
2000
Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage.
The Journal of biological chemistry. 275(34):26277-84 [PMID] 10816583.
View on: PubMed
2000
The presenilin 1 C92S mutation increases abeta 42 production.
Biochemical and biophysical research communications. 277(1):261-3 [PMID] 11027672.
View on: PubMed
1999
gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length.
The Journal of biological chemistry. 274(17):11914-23 [PMID] 10207012.
View on: PubMed
1999
A novel, non-nested reverse-transcriptase polymerase chain reaction (RT-PCR) test for the detection of the t(15;17) translocation: a comparative study of RT-PCR cytogenetics, and fluorescence In situ hybridization.
Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology. 4(3):195-209 [PMID] 10553020.
View on: PubMed
1996
Expression and analysis of presenilin 1 in a human neuronal system: localization in cell bodies and dendrites.
Proceedings of the National Academy of Sciences of the United States of America. 93(17):9223-8 [PMID] 8799182.
View on: PubMed
1994
Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer’s disease.
Annals of neurology. 36(6):903-11 [PMID] 7998778.
View on: PubMed
1994
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.
Science (New York, N.Y.). 264(5163):1336-40 [PMID] 8191290.
View on: PubMed
1993
Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides.
Proceedings of the National Academy of Sciences of the United States of America. 90(20):9513-7 [PMID] 8415732.
View on: PubMed
1993
Production of amyloid beta protein from normal amyloid beta-protein precursor (beta APP) and the mutated beta APPS linked to familial Alzheimer’s disease.
Annals of the New York Academy of Sciences. 695:103-8 [PMID] 8239266.
View on: PubMed
1993
Release of excess amyloid beta protein from a mutant amyloid beta protein precursor.
Science (New York, N.Y.). 259(5094):514-6 [PMID] 8424174.
View on: PubMed
1993
Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer’s disease.
The American journal of pathology. 143(3):886-93 [PMID] 8362984.
View on: PubMed
1992
Secretory processing of the Alzheimer amyloid beta/A4 protein precursor is increased by protein phosphorylation.
Biochemical and biophysical research communications. 187(3):1285-90 [PMID] 1417805.
View on: PubMed
1992
Processing of the amyloid protein precursor to potentially amyloidogenic derivatives.
Science (New York, N.Y.). 255(5045):728-30 [PMID] 1738847.
View on: PubMed
1992
Production of the Alzheimer amyloid beta protein by normal proteolytic processing.
Science (New York, N.Y.). 258(5079):126-9 [PMID] 1439760.
View on: PubMed
1992
Normal processing of the Alzheimer’s disease amyloid beta protein precursor generates potentially amyloidogenic carboxyl-terminal derivatives.
Annals of the New York Academy of Sciences. 674:138-48 [PMID] 1288359.
View on: PubMed
1992
Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor.
Science (New York, N.Y.). 255(5045):726-8 [PMID] 1738846.
View on: PubMed
1991
Serum amyloid P in Alzheimer’s disease. Implications for dysfunction of the blood-brain barrier.
Annals of the New York Academy of Sciences. 640:145-8 [PMID] 1776732.
View on: PubMed
1990
Analysis of the beta-amyloid protein precursor of Alzheimer’s disease: mRNAs and protein products.
Advances in neurology. 51:181-4 [PMID] 2104687.
View on: PubMed
1990
Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer’s disease using PCR.
Neuron. 4(2):253-67 [PMID] 2106330.
View on: PubMed
1989
The beta amyloid protein precursor: mRNAs, membrane-associated forms, and soluble derivatives.
Progress in clinical and biological research. 317:971-84 [PMID] 2513588.
View on: PubMed
1988
Amyloid protein precursor messenger RNAs: differential expression in Alzheimer’s disease
Science. 241:1080-1084
1988
Amyloid protein precursor messenger RNAs: differential expression in Alzheimer’s disease.
Science (New York, N.Y.). 241(4869):1080-4 [PMID] 2457949.
View on: PubMed
1988
Evolution of the IgA heavy chain gene in the genus Mus.
Genetics. 119(4):925-31 [PMID] 2842228.
View on: PubMed
1988
In situ hybridization of nucleus basalis neurons shows increased beta-amyloid mRNA in Alzheimer disease.
Proceedings of the National Academy of Sciences of the United States of America. 85(4):1227-31 [PMID] 3277188.
View on: PubMed
1986
Evolution of the mouse IgA gene: nucleotide sequence comparison of IgA in BALB/c and Mus pahari.
Current topics in microbiology and immunology. 127:141-8 [PMID] 3731840.
View on: PubMed

Grants

Sep 2020 ACTIVE
Identifying and understanding the role of repeat RNAs and RAN proteins in Alzheimer's disease
Role:
Funding: NATL INST OF HLTH NIA
Sep 2020 ACTIVE
A Systems Approach to Targeting Innate Immunity in AD
Role: Principal Investigator
Funding: MAYO CLINIC via NATL INST OF HLTH NIA
Aug 2020 ACTIVE
Interdisciplinary Training in Movement Disorders and Neurorestoration
Role:
Funding: NATL INST OF HLTH NINDS
Jun 2020 ACTIVE
1Florida Alzheimers Disease Research Center
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Sep 2019 ACTIVE
Modulation of Alzheimers disease by Herpes simplex virus infection
Role: Principal Investigator
Funding: UNIV OF WASHINGTON via NATL INST OF HLTH NIA
Aug 2019 ACTIVE
Elucidating factors that modulate tauopathy and cellular degeneration to guide therapeutic development
Role:
Funding: NATL INST OF HLTH NIA
Aug 2019 ACTIVE
Immunotherapy targeting the HPA axis in Alzheimers disease
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Sep 2018 – Aug 2020
A Systems Approach to Targeting Innate Immunity in AD
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Jul 2018 ACTIVE
Understanding and Targeting Tau-induced Neurodegeneration
Role: Project Manager
Funding: BRIGHTFOCUS FOU
Jun 2018 ACTIVE
APOE as a modifier of prion-like spread in dementia
Role:
Funding: NATL INST OF HLTH NIA
Feb 2018 – Aug 2020
Periodontal Bacteria augment Progression of Abeta and Tau Pathology
Role:
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Feb 2018 ACTIVE
Towards Understanding the Biological Role of Newly Discovered Alzheimers Disease Susceptibility Genes Affecting Immune Function
Role:
Funding: FL DEPT OF HLTH ED ETHEL MOORE ALZHEIMER
Sep 2017 ACTIVE
Immunotherapeutic Targeting of Corticotropin-Releasing Hormone in Alzheimers Disease
Role:
Funding: NATL INST OF HLTH NINDS
Sep 2017 – May 2018
APOE as a modifier of prion-like spread in dementia
Role:
Funding: NATL INST OF HLTH NIA
Aug 2017 – Jul 2020
Periodontal bacteria and Alzheimers disease
Role:
Funding: NATL INST OF HLTH NINDS
Jan 2016 ACTIVE
Miscellaneous Donors (Dr. Golde)
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Aug 2015 ACTIVE
University of Florida – Mt. Sinai Medical Center AD Research Center
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Aug 2015 – Dec 2016
Exploring the positive effects of rAAV-IL-10 in a ALS mo
Role: Principal Investigator
Funding: AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jul 2015 ACTIVE
NACC YR 17 DATA COORDINATING CENTER SUBAWARD
Role: Principal Investigator
Funding: UNIV OF WASHINGTON via NATL INST OF HLTH
Jun 2015 – May 2017
rAAV based somatic sheep brain and spinal cord
Role: Principal Investigator
Funding: UF DSR OPPORTUNITY FUND
May 2014 – Feb 2019
Immune-Mediated Mechanisms underlying CNS Abeta Clearance
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Sep 2013 – Aug 2019
Targeting Multiple Diseases Through Gamma Secretase
Role: Principal Investigator
Funding: UNIV OF MASSACHUSETTS via NATL INST OF HLTH NCI
Sep 2013 – Aug 2018
A Systems Approach to Targeting Innate Immunity in AD
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
Jul 2010 ACTIVE
Therapeutic Discovery in Neurodegenerative Disease
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO

Patents

Published April 2010
Reducing Abeta42 Levels and Abeta Aggregation (MAYO CLINIC)
#2011/0021471 A1
Published June 2018
Compounds For Treating Neurodegenerative Proteinopathies (DIV)
#US18/0355018
Issued July 2018
Compounds for Treating Neurodegenerative Proteinopathies
#10,030,067

Education

Chief Resident Clinical Pathology and Laboratory Medicine
1995-1996 · University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania
Resident Clinical Pathology and Laboratory Medicine
1994-1996 · University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania
Postdoctoral Fellow, Neuroscience Training Grant
1991-1992 · Case Western Reserve Universit ; Mentor: Steven G. Younkin M.D., Ph.D.
Research Associate
1990-1991 · Institute of Pathology Case Western Reserve University; Mentor: Steven G. Younkin, M.D. Ph.D
MD PhD, NIH funded Medical Scientist Training Program (MSTP)
1985-1994 · Case Western Reserve University
BA
1981-1985 · Amherst College

Teaching Profile

Courses Taught
2020
GMS6252 Molecular Therapy II ? Disease Targets and Applications
2019
GMS6757 Introduction to Alzheimer’s Disease and Related Dementias: Clinical and Mechanistic Principles
2018
GMS7980 Research for Doctoral Dissertation
2017
EGN4912 Engineering Directed Independent Research
2010-2013,2015-2016
GMS6750 Molecular Pathobiology of Neural Disease
2013-2015
GMS7794 Neuroscience Seminar
2013-2014
PHA5902 Research Pharmacodyna
2013
GMS6029 Brain Journal Club

Contact Details

Phones:
Business:
(352) 273-9456
Emails:
Business:
tgolde@ufl.edu